The aligned pathway, which launches on 1 April, will help to bring NICE's decision-making process forward to run alongside MHRA's, resulting in decisions on licencing and value being made at the same time.

Alongside the pathway, NICE and the MHRA are also launching an improved Integrated Scientific Advice service designed to help companies follow the aligned pathway timelines by clarifying regulations and the evidence required early in the development process. This is designed to help companies improve their clinical development plans and reduce unforeseen delays.

Dr Zubir Ahmed, health innovation and safety minister, said: ‘As a practising surgeon, I know how important it is that patients get access to the latest treatments as quickly as possible.

‘That's why we're cutting red tape so safe and effective new medicines can reach NHS patients up to six months sooner and get patients back to full health earlier.

‘Not only that, but this will also give companies clearer, quicker decisions - helping make the UK an even more attractive place to invest in life sciences and bring innovations to market, boosting the economy in the process.'